Levepsy XR 750 Tablet contains Levetiracetam 750 mg, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam is believed to exert its anticonvulsant effects by binding to synaptic vesicle protein 2A (SV2A) in the brain, modulating neurotransmitter release and thereby reducing neuronal excitability. Levepsy XR 750 is formulated as an extended-release tablet to provide sustained plasma concentrations, allowing once-daily dosing and improved patient compliance. It is typically prescribed as adjunctive therapy in adults and pediatric patients aged four years and older. The pharmacokinetic profile of Levetiracetam is characterized by rapid absorption, minimal hepatic metabolism, and predominant renal excretion, necessitating dose adjustments in patients with renal impairment. Common adverse effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or mood swings. Levepsy XR 750 should be used cautiously in patients with a history of psychiatric disorders. It is contraindicated in individuals with known hypersensitivity to Levetiracetam or any tablet components. As with all antiepileptic drugs, abrupt discontinuation should be avoided to prevent seizure exacerbation. Regular monitoring and adherence to prescribed dosing are essential for optimal therapeutic outcomes.